Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 7/2016

01-05-2016 | Current Opinion

Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction

Authors: Gerd Heusch, Petra Kleinbongard

Published in: Drugs | Issue 7/2016

Login to get access

Abstract

Ivabradine inhibits hyperpolarization-activated cyclic nucleotide-gated channels in the sinus node, thereby reducing heart rate, and heart rate reduction improves regional myocardial blood flow and contractile function in ischemic myocardium. Accordingly, ivabradine reduces anginal symptoms in patients with stable coronary artery disease but does not improve their clinical outcome. Heart rate reduction with ivabradine in patients with symptomatic heart failure reduces symptoms, attenuates remodeling, and improves clinical outcome. In pigs and mice, ivabradine reduces infarct size from myocardial ischemia/reperfusion, even when heart rate reduction is abrogated by atrial pacing. Improved viability is also observed in isolated ventricular cardiomyocytes subjected to simulated ischemia/reperfusion. These beneficial effects are attributed to reduced reactive oxygen species formation from the mitochondria. There is also evidence for a heart rate-independent benefit from ivabradine in the vasculature of mice and humans, and in left ventricular contractile function of pigs. Finally, in mice, ivabradine also has anti-aging potential.
Literature
1.
DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I f current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs. 2004;64:1757–65.CrossRefPubMed
2.
Borer JS. Drug insight: I f inhibitors as specific heart-rate-reducing agents. Nature. 2004;1:103–9.
3.
Custodis F, Reil JC, Laufs U, Bohm M. Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol. 2013;62:183–7.CrossRefPubMed
4.
Roubille F, Tardif JC. New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels. Circulation. 2013;127:1986–96.CrossRefPubMed
5.
Tanaka N, Nozawa T, Yasumura Y, Futaki S, Hiramori K, Suga H. Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol. 1990;40:503–21.CrossRefPubMed
6.
Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153:1589–601.CrossRefPubMedPubMedCentral
7.
Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010;56:1973–83.CrossRefPubMed
8.
Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther. 2004;308:236–40.CrossRefPubMed
9.
Heusch G, Yoshimoto N, Müller-Ruchholtz ER. Effects of heart rate on hemodynamic severity of coronary artery stenosis in the dog. Basic Res Cardiol. 1982;77:562–73.CrossRefPubMed
10.
Flameng W, Wüsten B, Winkler B, Pasyk S, Schaper W. Inluence of perfusion pressure and heart rate on local myocardial flow in the collateralized heart with chronic coronary occlusion. Am Heart J. 1975;89:51–9.CrossRefPubMed
11.
Neill WA, Oxendine JM, Phelps NC, Anderson RP. Subendocardial ischemia provoked by tachycardia in conscious dogs with coronary stenosis. Am J Cardiol. 1975;35:30–6.CrossRefPubMed
12.
Heusch G, Yoshimoto N. Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflügers Arch. 1983;397:284–9.CrossRefPubMed
13.
Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008;29:2265–75.CrossRefPubMed
14.
Buck JD, Hardman HF, Warltier DC, Gross GJ. Changes in ischemic blood flow distribution and dynamic severity of a coronary stenosis induced by beta blockade in the canine heart. Circulation. 1981;64:708–15.CrossRefPubMed
15.
Heusch G, Deussen A. The effects of cardiac sympathetic nerve stimulation on the perfusion of stenotic coronary arteries in the dog. Circ Res. 1983;53:8–15.CrossRefPubMed
16.
Seitelberger R, Guth BD, Heusch G, Lee JD, Katayama K, Ross J Jr. Intracoronary a2-adrenergic receptor blockade attenuates ischemia in conscious dogs during exercise. Circ Res. 1988;62:436–42.CrossRefPubMed
17.
18.
Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess O, et al. α-Adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation. 2000;101:689–94.CrossRefPubMed
19.
Simon L, Ghaleh B, Puybasset L, Giudicelli J-F, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275:659–66.PubMed
20.
Guth BD, Heusch G, Seitelberger R, Ross J Jr. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res. 1987;60:738–46.CrossRefPubMed
21.
Colin P, Ghaleh B, Monnet X, Su J, Hittinger L, Giudicelli J-F, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284:H676–82.CrossRefPubMed
22.
Berdeaux A, Peres da Costa C, Garnier M, Boissier JR, Giudicelli JF. Beta adrenergic blockade, regional left ventricular blood flow and ST-segment elevation in canine experimental myocardial ischemia. J Pharmacol Exp Ther. 1978;205:646–56.PubMed
23.
Matsuzaki M, Patritti J, Tajimi T, Miller M, Kemper WS, Ross J Jr. Effects of β-blockade on regional myocardial flow and function during exercise. Am J Physiol. 1984;247:H52–60.PubMed
24.
Johannsen UJ, Mark AL, Marcus ML. Responsiveness to cardiac sympathetic nerve stimulation during maximal coronary dilation produced by adenosine. Circ Res. 1982;50:510–7.CrossRefPubMed
25.
Baumgart D, Ehring T, Kowallik P, Guth BD, Krajcar M, Heusch G. The impact of a-adrenergic coronary vasoconstriction on the transmural myocardial blood flow distribution during humoral and neuronal adrenergic activation. Circ Res. 1993;73:869–86.CrossRefPubMed
26.
Giudicelli JF, Berdeaux A, Tato F, Garnier M. Left stellate stimulation: regional myocardial flows and ischemic injury in dogs. Am J Physiol. 1980;239:H359–64.PubMed
27.
Berkenboom GM, Abramowicz M, Vandermoten P, Degre SG. Role of alpha-adrenergic coronary tone in exercise-induced angina pectoris. Am J Cardiol. 1986;57:195–8.CrossRefPubMed
28.
Gregorini L, Marco J, Kozàkovà M, Palombo C, Anguissola GB, Marco I, et al. α-Adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation. 1999;99:482–90.CrossRefPubMed
29.
Baumgart D, Haude M, Goerge G, Liu F, Ge J, Große-Eggebrecht C, et al. Augmented α-adrenergic constriction of atherosclerotic human coronary arteries. Circulation. 1999;99:2090–7.CrossRefPubMed
30.
Gregorini L, Marco J, Farah B, Bernies M, Palombo C, Kozakova M, et al. Effects of selective α1- and α2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation. 2002;106:2901–7.CrossRefPubMed
31.
Heusch G. The paradox of alpha-adrenergic coronary vasoconstriction revisited. J Mol Cell Cardiol. 2011;51:16–23.CrossRefPubMed
32.
Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I f inhibitor, in stable angina. Circulation. 2003;107:817–23.CrossRefPubMed
33.
Ruzyllo W, Ford IF, Tendera MT, Fox KF. Antianginal and antiischaemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial. Eur Heart J. 2004;25:A878.
34.
Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–36.CrossRefPubMed
35.
Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67:393–405.CrossRefPubMed
36.
Lopez-Bescos L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108:387–96.CrossRefPubMed
37.
Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.CrossRefPubMed
38.
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30:2337–45.CrossRefPubMed
39.
Heusch G. A BEAUTIFUL lesson: ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur Heart J. 2009;30:2300–1.CrossRefPubMed
40.
Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–9.CrossRefPubMed
41.
Neumann T, Ravens U, Heusch G. Characterization of excitation-contraction coupling in conscious dogs with pacing-induced heart failure. Cardiovasc Res. 1998;37:456–66.CrossRefPubMed
42.
Mahler F, Yoran C, Ross J Jr. Inotropic effects of tachycardia and poststimulation potentiation in the conscious dog. Am J Physiol. 1974;227:569–75.PubMed
43.
44.
Miura T, Miyazaki S, Guth BD, Kambayashi M, Ross J Jr. Influence of the force–frequency relation on left ventricular function during exercise in conscious dogs. Circulation. 1992;86:563–71.CrossRefPubMed
45.
Eising GP, Hammond HK, Helmer GA, Gilpin E, Ross J Jr. Force–frequency relations during heart failure in pigs. Am J Physiol. 1994;267:H2516–22.PubMed
46.
Heinzel FR, Luo Y, Dodoni G, Boengler K, Petrat F, Di Lisa F, et al. Formation of reactive oxygen species at increased contraction frequency in rat cardiomyocytes. Cardiovasc Res. 2006;71:374–82.CrossRefPubMed
47.
Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, Just H. Influence of the force–frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J. 1994;15:164–70.CrossRefPubMed
48.
Neumann T, Heusch G. Myocardial, skeletal muscle, and renal blood flow during exercise in conscious dogs with heart failure. Am J Physiol Heart Circ Physiol. 1997;273:H2452–7.
49.
Heusch G, Neumann T. Calcium responsiveness in canine pacing-induced heart failure. J Mol Cell Cardiol. 1998;30:1605–13.CrossRefPubMed
50.
Neumann T, Vollmer A, Schaffner T, Hess OM, Heusch G. Diastolic dysfunction and collagen structure in canine pacing-induced heart failure. J Mol Cell Cardiol. 1999;31:179–92.CrossRefPubMed
51.
Moe GW, Armstrong P. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res. 1999;42:591–9.CrossRefPubMed
52.
McLaran CJ, Gersh BJ, Sugrue DD, Hammill SC, Seward JB, Holmes DR Jr. Tachycardia induced myocardial dysfunction. A reversible phenomenon? Br Heart J. 1985;53:323–7.CrossRefPubMedPubMedCentral
53.
Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563–70.CrossRefPubMed
54.
Nerheim P, Birger-Botkin S, Piracha L, Olhansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110:247–52.CrossRefPubMed
55.
Custodis F, Roggenbuck U, Lehmann N, Moebus S, Laufs U, Mahabadi AA, et al. Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. Clin Res Cardiol. Epub 23 Jan 2016.
56.
Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886–94.CrossRefPubMed
57.
Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823–30.CrossRefPubMed
58.
Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865–9.CrossRefPubMed
59.
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875–85.CrossRefPubMed
60.
Tardif JC, O’Meara E, Komajda M, Bohm M, Borer JS, Ford I, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–15.CrossRefPubMedPubMedCentral
61.
Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol. 2008;155:970–1.CrossRefPubMedPubMedCentral
62.
Kleinbongard P, Gedik N, Witting P, Freedman B, Klocker N, Heusch G. Pleiotropic, heart rate-independent cardioprotection by ivabradine. Br J Pharmacol. 2015;172:4380–90.CrossRefPubMed
63.
Herrmann S, Layh B, Ludwig A. Novel insights into the distribution of cardiac HCN channels: an expression study in the mouse heart. J Mol Cell Cardiol. 2011;51:997–1006.CrossRefPubMed
64.
Hofmann F, Fabritz L, Stieber J, Schmitt J, Kirchhof P, Ludwig A, et al. Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. Cardiovasc Res. 2012;95:317–26.CrossRefPubMed
65.
Cerbai E, Sartiani L, DePaoli P, Pino R, Maccherini M, Bizzarri F, et al. The properties of the pacemaker current If in human ventricular myocytes are modulated by cardiac disease. J Mol Cell Cardiol. 2001;33:441–8.CrossRefPubMed
66.
Stillitano F, Lonardo G, Zicha S, Varro A, Cerbai E, Mugelli A, et al. Molecular basis of funny current If in normal and failing human heart. J Mol Cell Cardiol. 2008;45:289–99.CrossRefPubMed
67.
Steg P, Lopez-de-Sa E, Schiele F, Hamon M, Meinertz T, Goicolea J, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care. 2013;2:270–9.CrossRefPubMedPubMedCentral
68.
Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post- and remote conditioning. Circ Res. 2015;116:674–99.CrossRefPubMed
69.
Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65:1454–71.CrossRefPubMed
70.
Rienzo M, Melka J, Bize A, Sambin L, Jozwiak M, Su JB, et al. Ivabradine improves left ventricular function during chronic hypertension in conscious pigs. Hypertension. 2015;65:122–9.CrossRefPubMed
71.
Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli J-F, Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J. 2004;25:579–86.CrossRefPubMed
72.
Maranta F, Tondi L, Agricola E, Margonato A, Rimoldi O, Camici PG. Ivabradine reduces myocardial stunning in patients with exercise-inducible ischaemia. Basic Res Cardiol. 2015;110:55.CrossRefPubMed
73.
Bolli R. Causative role of oxyradicals in myocardial stunning: a proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction. Basic Res Cardiol. 1998;93:156–62.CrossRefPubMed
74.
Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E deficient mice. Circulation. 2008;117:2377–87.CrossRefPubMed
75.
Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008;154:749–57.CrossRefPubMedPubMedCentral
76.
Skalidis EI, Hamilos MI, Chlouverakis G, Zacharis EA, Vardas PE. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis. 2011;215:160–5.CrossRefPubMed
77.
Tagliamonte E, Cirillo T, Rigo F, Astarita C, Coppola A, Romano C, et al. Ivabradine and bisoprolol on doppler-derived coronary flow velocity reserve in patients with stable coronary artery disease: beyond the heart rate. Adv Ther. 2015;32:757–67.CrossRefPubMedPubMedCentral
78.
79.
Gent S, Kleinbongard P, Dammann P, Neuhauser M, Heusch G. Heart rate reduction and longevity in mice. Basic Res Cardiol. 2015;110:2.CrossRefPubMed
80.
Coburn AF, Grey RM, Rivera SM. Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A-J mouse. Johns Hopkins Med J. 1971;128:169–93.PubMed
81.
Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2012;11:390–8.CrossRefPubMedPubMedCentral
Metadata
Title
Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction
Authors
Gerd Heusch
Petra Kleinbongard
Publication date
01-05-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 7/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0567-2

Other articles of this Issue 7/2016

Drugs 7/2016 Go to the issue

AdisInsight Report

Obiltoxaximab: First Global Approval

Current Opinion

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century

Review Article

Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy

Review Article

Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia

Review Article

Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

Adis Drug Evaluation

Susoctocog Alfa: A Review in Acquired Haemophilia A